T89
Phase 3Small molecule
T89 is one of 38 small molecule programs targeting COVID-19. It is currently in Phase 3.
2
Indications
9
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1T89
TTasly Pharmaceuticals, Inc.
Phase 3
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Activella
Eli LillyPreclinical
Calciferol
Jazz PharmaceuticalsPreclinical
Tricor
JJagotec
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Benadryl
PParkedale
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-192 trials
Acute Mountain Sickness (AMS)2 trials
Outcome1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for T89. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTasly Pharmaceuticals, Inc.